feed,title,long_url,short_url
Benzinga,CStone and EQRx Enter Global Strategic Partnership for Two Immune Checkpoint Inhibitors: sugemalimab (anti-PD-L1) and CS1003 (anti-PD-1),https://www.benzinga.com/pressreleases/20/10/n18065345/cstone-and-eqrx-enter-global-strategic-partnership-for-two-immune-checkpoint-inhibitors-sugemalima,https://j.mp/3jzOnMW
Benzinga,CStone and EQRx Enter Global Strategic Partnership for Two Immune Checkpoint Inhibitors: sugemalimab (anti-PD-L1) and CS1003 (anti-PD-1),https://www.benzinga.com/pressreleases/20/10/n18065343/cstone-and-eqrx-enter-global-strategic-partnership-for-two-immune-checkpoint-inhibitors-sugemalima,https://j.mp/3jAZG7v
